The Innovative Medicines Initiative, a joint undertaking of the European Union and the European Federation of Pharmaceutical Industries and Associations, launched OPTIMA, a €21.3 million public-private research program that will seek to use artificial intelligence to improve care for patients with prostate, breast, and lung cancer.
When President Donald Trump on Feb. 3 signed H.R.7148, a package funding most of the federal government through FY26, many in oncology released a long-held sigh of relief.
